RA is a chronic disease that has multiple and fluctuating symptoms. Because no one measure can adequately capture disease activity or severity.

Proteolytic enzymes in RA are grounded in their observed anti-inflammatory properties, which can potentially mitigate the chronic inflammation characteristic of RA joints. These enzymes, such as bromelain, papain, trypsin, and chymotrypsin, may modulate inflammatory pathways by degrading cytokines and other inflammatory mediators. Additionally, they show promise in promoting tissue repair and regeneration, essential for combating joint damage and erosion in RA. Studies suggest that proteolytic enzymes could help restore immune balance by influencing cytokine profiles and immune cell function. Clinical evidence supports their role in reducing pain and improving joint function, offering a complementary therapeutic approach alongside conventional RA treatments.

This trial is also designed to investigate whether oral proteolytic enzymes could provide systemic relief from gastrointestinal symptoms, which are commonly associated with the DMARDs. Specifically, the study aimed to assess the enzymes’ potential in alleviating heartburn, gastric discomfort, and epigastric pain in individuals with rheumatoid arthritis, offering a potentially safer alternative or adjunct to conventional DMARD therapy.

Moreover, their natural origin often ensures better tolerability and safety profiles compared to synthetic medications, making them appealing for participants seeking alternative or adjunctive therapies for RA management. The aim of the study was to evaluate the efficacy and safety of an oral enzyme supplement (EnMax DS) with the placebo.